Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 445

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 445
---
 was formed in 2015. Prior to a career in investment, Dr. Liu had a successful Internet start -upexperience and had also worked as a consultant at McKinsey & Company. Dr. Liu currently serves on the boards of directors of 3E BioPartners Ltd., 3E Bioventure Partners, LLC, and Beijing 3E Bioventures Investment Management Co.Ltd. Dr. Liu received a Ph.D. in Immunology from Harvard University, Master of Medical Sciences degree from Harvard Medical School, and Bachelor of Sciences degree from Cornell University. She also received an EMBA degree from CKGSB — Chungkong Graduate School of Business in China. Siu Wai Ng— Mr. Ng has served as a member of Profusa’s board of directors since April 2018. Mr. Ng has more than 14 years of industry experience, and has been the Head of Healthcare in the Private Equity Department at VMS Group, an asset management firm, since April 2017 and a Managing Director since March 2018. He has also served as an Investment Partner of Panacea Venture Management Company Ltd, a healthcare focused venture capital firm, since July 2021. Prior to joining VMS Group, Mr. Ng was the lead analyst for the China Healthcare Equity Research from September 2015 to April 2016 and an associate then vice president of the healthcare investment banking division from September 2011 to August 2015 at Barclays Capital Asia Limited. Mr. Ng has served as a director of

251 companies that carry out product development, manufacturing and sales in the biotechnology, medical equipment and biologics contract development and manufacturing industries. Mr. Ng obtained a Bachelor of Science degree in January 2007 and a Master of Engineering degree in Operations Research and Industrial Engineering in May 2007 from Cornell University, the United States. In July 2011, Mr. Ng obtained a Master of Business Administration from INSEAD in Singapore. Election of Officers Profusa’s executive officers are appointed by, and serve at the discretion of, Profusa’s board of directors. There are no family relationships among any of Profusa’s directors or executive officers. 252

EXECUTIVE AND DIRECTOR COMPENSATION OF PROFUSA This section discusses the material components of the executive compensation program for Profusa’s named executive officers identified in the 2023 Summary Compensation Table below. This discussion may contain forward -lookingstatements that are based on New Profusa’s current plans, considerations, expectations and determinations regarding future